康柏西普玻璃体腔注射联合格栅样光凝治疗糖尿病性黄斑水肿的疗效观察

发布时间：2018-03-23 16:16

本文选题：糖尿病性黄斑水肿　切入点：康柏西普　出处：《临床医学研究与实践》2016年05期

【摘要】：目的观察康柏西普玻璃体腔注射联合格栅样光凝治疗糖尿病性黄斑水肿(DME)的效果。方法对46例,50只眼DME患者采用玻璃体腔注射康柏西普0.1 m L治疗,2周后采用氩离子激光对黄斑区进行格栅样光凝,治疗后随访6个月,观察治疗前后最佳矫正视力、眼底、眼压、光学相干断层扫描(OCT)、荧光素眼底血管造影(FFA)黄斑区改变。结果所有患者治疗后视力从术前(0.23±0.08)增加至术后(0.43±0.13),黄斑水肿消退或减轻,治疗前后差异有统计学意义(P0.05)。随访期间未发生眼内炎、视网膜脱离、玻璃体积血等并发症。结论康柏西普玻璃体腔注射联合格栅样光凝治疗可有效减轻糖尿病引起的黄斑水肿,提高视力,但远期疗效仍有待观察。
[Abstract]:Objective to observe the effect of Corbeseptide intravitreal injection combined with grid photocoagulation in the treatment of diabetic macular edema. Methods 46 cases (50 eyes) of DME were treated by intravitreal injection of Corbeseptide 0.1 mL for 2 weeks with argon. Ion laser photocoagulation in the macular region is grid-like. The best corrected visual acuity (BCVA), fundus, intraocular pressure (IOP) were observed after 6 months follow-up. Results after treatment, the visual acuity of all the patients increased from 0.23 卤0.08 to 0.43 卤0.13, macular edema subsided or alleviated. There were no complications such as endophthalmitis, retinal detachment, vitreous hemorrhage and so on during the follow-up period. Conclusion Comborsup intravitreal injection combined with grid photocoagulation can effectively reduce macular edema caused by diabetes. Visual acuity was improved, but the long-term effect remained to be observed.
【作者单位】：新乡医学院第三附属医院;
【分类号】：R774.5;R587.2

【相似文献】